Emergent BioSolutions Inc. Form 4/A Filed 2017-02-24

FORM 4

☐	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0287
Expires:	02/28/2011
Estimated average burden
hours per response		0.5

1. Name and Address of Reporting Person ^*

Kramer Robert

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [EBS]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
EVP, Corporate Services Divisi

(Last)

(First)

(Middle)

400 PROFESSIONAL DR, SUITE 400

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2016

(Street)

GAITHERSBURG, MD 20879

(City)

(State)

(Zip)

4. If Amendment, Date Original Filed(Month/Day/Year)
04/05/2016

6. Individual or Joint/Group Filing(Check applicable line)

__X__ Form Filed by One Reporting Person
_____ Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock⁽²⁾	04/01/2016		M		11,531	A	$14.41	91,607	D
Common Stock⁽²⁾	04/01/2016		S⁽¹⁾		11,531	D	$35.49⁽⁶⁾	80,076	D
Common Stock⁽³⁾	04/01/2016		M		3,939	A	$14.67	84,015	D
Common Stock⁽³⁾	04/01/2016		S⁽¹⁾		3,939	D	$35.74⁽⁷⁾	80,076	D
Common Stock⁽⁴⁾	04/01/2016		M		17,354	A	$28.09	97,430	D
Common Stock⁽⁴⁾	04/01/2016		S⁽¹⁾		17,354	D	$35.48⁽⁸⁾	80,076	D
Common Stock⁽⁵⁾	04/01/2016		M		5,503	A	$29	85,579	D
Common Stock⁽⁵⁾	04/01/2016		S⁽¹⁾		5,503	D	$35.66⁽⁹⁾	80,076	D
Common Stock⁽¹⁰⁾	04/01/2016		S⁽¹⁾		445	D	$35.93⁽¹¹⁾	79,631	D
Common Stock⁽¹⁰⁾	04/01/2016		S⁽¹⁾		1,855	D	$35.8⁽¹²⁾	77,776	D
Common Stock⁽¹⁰⁾	04/01/2016		S⁽¹⁾		2,945	D	$35.73⁽¹³⁾	74,831	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Stock Option⁽²⁾

$14.41

04/01/2016

11,531

⁽¹⁴⁾

11/04/2019

Common Stock

11,531

$ 0

11,531

Stock Option⁽³⁾

$14.67

04/01/2016

3,939

⁽¹⁵⁾

03/11/2020

Common Stock

3,939

$ 0

3,940

Stock Option⁽⁴⁾

$28.09

04/01/2016

17,354

⁽¹⁶⁾

03/10/2021

Common Stock

17,354

$ 0

34,708

Stock Option⁽⁵⁾

$29

04/01/2016

5,503

⁽¹⁷⁾

03/09/2022

Common Stock

5,503

$ 0

27,514

Explanation of Responses:

1.	These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016.
2.	Consists of an option granted under the company's stock incentive plan on November 5, 2012.
3.	Consists of an option granted under the company's stock incentive plan on March 12, 2013.
4.	Consists of an option granted under the company's stock incentive plan on March 11, 2014.
5.	Consists of an option granted under the company's stock incentive plan on March 10, 2015.
6.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.34, inclusive.
7.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.32, inclusive.
8.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.07 to $36.35, inclusive.
9.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.12 to $36.42, inclusive.
10.	Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
11.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.00, inclusive.
12.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.13, inclusive.
13.	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.32, inclusive.
14.	The option vested in three equal installments in November 2013, 2014 and 2015.
15.	The option vest in three equal installments in March 2014, 2015 and 2016.
16.	The option vest in three equal installments in March 2015, 2016 and 2017.
17.	The option vest in three equal installments in March 2016, 2017 and 2018.
Remarks: EXPLANATORY NOTE: The sole purpose of this amendment to the Form 4 is to denote that the execution of all of the sale transactions reported by this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 29, 2016.

	Signatures
	/s/ Eric Burt, attorney-in-fact	02/24/2017
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.